Abstract
β2-microglobulin has been observed to behave as a biological marker of bone remodeling. We measured β2-microglobulin and tartrate-resistant acid phosphatase (TRAP), a specific biological marker of bone remodeling, in 225 women: healthy premenopausal controls, healthy postmenopausal controls, and patients with diseases characterized by enhanced bone turnover (postmenopausal osteoporosis, primary hyperparathyroidism, primary hyperthyroidism, polyostotic Paget's bone disease), and in other Paget's group before and after calcitonin treatment. β2-microglobulin levels differed significantly between the healthy premenopausal women (n=38) and the women with hyperparathyroidism (n=20) compared with all the other groups. However, β2-microglobulin levels did not differ significantly between healthy postmenopausal women (n=38) and patients with Paget's bone disease (n=40) (P=0.5095), or between women with postmenopausal osteoporosis (n=30) and women with hyperthyroidism (n=20) (P=0.7890). TRAP concentrations differed significantly in all the groups paired except for women with Paget's bone disease and women with either hyperparathyroidism or hyperthyroidism (P=0.5179 and 0.6993, respectively); likewise, TRAP levels did not differ significantly between the women with hyperparathyroidism and those with hyperthyroidism (P=0.7804). After calcitonin treatment, there was a 22% increase in β2-microglobulin, a 17% decrease in TRAP, and a 39% decrease in alkaline phosphatase, all of which were significant at P<0.0001. Our findings indicate that serum β2-microglobulin, like osteocalcin, behaves as a biological marker of remodeling in a number of diseases with enhanced bone remodeling but not in Paget's bone disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rico H, Ripoll E, Revilla M, Relea P, Villa LF (1993) 275-1 in postmenopausal osteoporosis. Calcif Tissue Int 53:78–80.
Rico H, Ripoll E, Revilla M, Arribas I, Gonzalez-Riola J (1993). La β2-microglobulin y su sugerencia como marcador del remodelamiento óseo. Rev Esp Enf Metab Oseas 2:176–178.
Rico H, Ripoll E, Arribas I, Revilla M, Relea P, Villa LF, Alvarez de Buergo Ma (1994). β2-microglobulin in Paget's bone disease. Calcif Tissue Int 54:389–391.
Franck WA, Bress NM, Singer FR, Krane SM (1974) Rheumatic manifestations of Paget's disease of bone. Am J Med 56:592–603.
Jaworski ZFG (1983). Histomorphometric characteristics of metabolic bone disease. In: Recker RR ed. Bone histomorphometry: techniques and interpretation. CRC Press, Boca Raton. Florida. pp 241–263.
Seiler D, Nagal D, Tritschler W, Looser S (1983) Acid phosphatase in serum (substrate:alpha-naphthyl-phosphate): reference values and diagnostic significance. J Clin Chem Clin Biochem 21:519–525.
Lam KW, Yam YT (1977). Biochemical characterization of the tartrate-resistant acid phosphatase of human spleen with leukemic reticuloendotheliosis as a pyrophosphatase. Clin Chem 23: 89–94.
Rico H, Villa LF (1993). Serum tartrate-resistant acid phosphatase as a biochemical marker of bone remodeling. Calcif Tissue Int 52:149–150.
Merkow RL, Lane JM (1984). Current concepts of Paget's disease of bone. Orthop Clin North Am 15:747–763.
Bijvoet OLM, van der Sluys Veer J, Jansen AP (1968). Effects of calcitonin on patients with Paget's disease, thyrotoxicosis, or hypercalcemia. Lancet 1:876–881.
Haddad JG, Couranz S, Avioli LV (1970). Nondialyzable urinary hydroxyproline as an index of bone collagen formation. J Clin Endocrinol Metab 30:282–287.
Descos L, Andre C, Beorghia S, Vincent C, Revillard JP (1979). Serum levels of β2-microglobulin—a new marker of activity in Crohn's disease. New Engl J Med 302:440.
Canalis E, McCarthy T, Centrella M (1987) A bone-derived growth factor isolated from rat calvaria is beta 2 microglobulin. Endocrinology 121:1198–2000.
Canalis E, McCarthy T, Centrella M (1988) Isolation of growth factors from adult bovine bone. Calcif Tissue Int 43:346–351.
Centrella M, Canalis E (1985). Transforming and nontransforming growth factors are present in medium conditioned by fetal rat calvariae. Proc Nat Acad Sci USA 82:7335–7339.
Canalis E, McCarthy T, Centrella M (1989) The regulation of bone formation by local growth factors. In: Peck WA, ed. Bone and Mineral Research/6. Elsevier Publisher. Amsterdam. pp 27–56.
Moe SM, Sprague SM (1992) Beta2-microglobulin induces calcium efflux from cultured neonatal mouse calvariae. Am J Physiol 263:F540-F545.
Canalis E, McCarthy T, Centrella M (1991) Growth factors and cytokines in bone cell metabolism. Annu Rev Med 42:17–24
Johansen JS, Williamson MK, Rice JS, Price PA (1992). Identification of proteins secreted by human osteoblastic cells in culture. J Bone Mineral Res 7:501–512.
Beresford JN, Gallagher JA, Poser JW, Russell RGG (1984). Production of osteocalcin by human bone cells in vitro. Metab Bone Dis 5:229–234.
Rude RK, Singer FR (1982). Hormonal modifiers of mineral metabolism other than parathyroid hormone, vitamin D and calcitonin. In: Bronner F, Coburn JW, eds. Disorders of mineral metabolism, vol II. Academic Press, New York, pp 481–556.
Laitinen O, Nikkila EA, Kivirikko KI (1966) Hydroxyproline in the serum and urine. Acta Med Scand 179:275–284.
Melsen F, Mosekilde L, Kragstrup J (1983). Metabolic bone disease as evaluated by bone histomorphometry. In: Recker RR (ed) Bone histomorphometry: techniques and interpretation. CRC Press. Boca Raton, Florida, pp 265–284.
Macleod JM, Mchardy KC, Harvey RD, Duncan A, Reid IW, Bewsher PD, Robins SP (1993). The early effects of radioiodine therapy for hyperthyroidism on biochemical indices of bone turnover. Clinical Endocrinology 38:49–53.
Scarnecchia L, Minisola S, Pacitti MT, Carnevale V, Romagnoli E, Rosso R, Mazzuoli GF (1991). Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover. Scand J Clin Lab Invest 51:517–524.
Cosman F, Shen V, Xie F, Seibel M, Ratcliffe A, Lindsay R (1993). Estrogen protection against bone resorbing effects of parathyroid hormone infusion-assessment by use of biochemical markers. Ann Intern Med 118:337–343.
Rico H, Cabranes JA, Almoguera I, Hernandez ER, Arroyo M (1987). Osteocarcina en la enfermedad osea de Paget: evidencia de su reutilizacion en la nueva osteoformacion. Med Clin (Barc) 88:13–15.
Merle B, Delmas PD (1990). Normal carboxylation of circulating osteocalcin (bone Gla-protein) in Paget's disease of bone. Bone Miner 11:237–245.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ripoll, E., Arribas, I., Relea, P. et al. Beta-2-microglobulin in diseases with high bone remodeling. Calcif Tissue Int 57, 272–276 (1995). https://doi.org/10.1007/BF00298882
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00298882